PAC1 receptor–mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain

Targeted protein degraders crowd into the clinic

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

(2020) Renaud La Joie et al.   Science Translational Medicine

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

(2020) Simon Dujardin et al.   NATURE MEDICINE

cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases

(2020) Jordan J. S. VerPlank et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation

(2019) Jordan J. S. VerPlank et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice

(2019) Julia Gamache et al.   Nature Communications

Tau local structure shields an amyloid-forming motif and controls aggregation propensity

(2019) Dailu Chen et al.   Nature Communications

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy

(2018) Thomas E Cope et al.   BRAIN

Discovery of PACAP and its receptors in the brain

(2018) Takahiro Hirabayashi et al.   JOURNAL OF HEADACHE AND PAIN

Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline

(2018) Ari W. Schaler et al.   Translational Research

A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers

(2018) Tiffany A. Thibaudeau et al.   Nature Communications

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

(2018) Ming-Kai Chen et al.   JAMA Neurology

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain

(2018) Sarah L. DeVos et al.   Frontiers in Neuroscience

Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems

(2018) Varunvenkatesh Balaji et al.   Autophagy

Trends in GPCR drug discovery: new agents, targets and indications

(2017) Alexander S. Hauser et al.   NATURE REVIEWS DRUG DISCOVERY

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

(2017) Chenjie Xia et al.   JAMA Neurology

Widespread tau seeding activity at early Braak stages

(2016) Jennifer L. Furman et al.   ACTA NEUROPATHOLOGICA

Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

(2016) Martijn C. de Wilde et al.   Alzheimers & Dementia

Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice

(2016) Jing L. Guo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Adenosine A1receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280

(2016) Frank J. A. Dennissen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease

(2015) Heiko Braak et al.   BRAIN

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis

(2015) Xing Guo et al.   NATURE CELL BIOLOGY

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

(2015) Natura Myeku et al.   NATURE MEDICINE

cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins

(2015) Sudarsanareddy Lokireddy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

(2014) David W. Sanders et al.   NEURON

Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology

(2013) Beatriz G. Perez-Nievas et al.   BRAIN

The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System

(2012) Hwan-Ching Tai et al.   AMERICAN JOURNAL OF PATHOLOGY

A role of protein degradation in memory consolidation after initial learning and extinction learning in the honeybee (Apis mellifera)

(2012) J. Felsenberg et al.   LEARNING & MEMORY

Propagation of Tau Pathology in a Model of Early Alzheimer's Disease

(2012) Alix de Calignon et al.   NEURON

Trans-Synaptic Spread of Tau Pathology In Vivo

(2012) Li Liu et al.   PLoS One

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity

(2011) X. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration

(2010) Brian R. Hoover et al.   NEURON

Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

(2009) D. Vaudry et al.   PHARMACOLOGICAL REVIEWS

Reversal of long-term dendritic spine alterations in Alzheimer disease models

(2009) D. L. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of PACAP in Ischemic Neural Death

(2008) Hirokazu Ohtaki et al.   JOURNAL OF MOLECULAR NEUROSCIENCE